CTOs on the Move

Potenza Therapeutics

www.potenzatherapeutics.com

 
Potenza Therapeutics is a biotechnology company focused on building a diverse portfolio of oncology programs that utilize the body`s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms. Our programs are built upon novel biological insights into the tumor microenvironment and mechanisms by which cancer cells evade detection and destruction by the immune system. Potenza Therapeutics was founded in 2014 and is located in Cambridge, MA.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Potenza Therapeutics raised $30M on 03/17/2016

Similar Companies

Y-mAbs Therapeutics

YmAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.

Progressive Medical

Progressive Medical is a Westerville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

5 hour energy

5 hour energy is a Farmington, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vaxart

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immuno-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

CardiaLen

Established in 2008, Cardialen, Inc., set out to develop an implantable defibrillator using low-electrical energy to restore normal heart rhythm and potentially avoid the negative side-effects of current therapies.